# An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

> **NCT04447716** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Thomas Jefferson University** · enrollment: 4 (actual)

## Conditions studied

- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Indolent Adult Non-Hodgkin Lymphoma
- Recurrent Marginal Zone Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Follicular Lymphoma
- Refractory Indolent Adult Non-Hodgkin Lymphoma
- Refractory Marginal Zone Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Lenalidomide
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Rituximab and Hyaluronidase Human

## Key facts

- **NCT ID:** NCT04447716
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-16
- **Primary completion:** 2024-05-16
- **Final completion:** 2027-04
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2025-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04447716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04447716, "An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04447716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*